2024 ´ç´¢º´ Ç÷°üÁúȯ ½ÉÆ÷Áö¾ö : 2024-02-17
±³À°ÀÏÀÚ : 2024-02-17
±³À°Àå¼Ò : aT¼¾ÅÍ 4Ãþ âÁ¶·ë
±³À°ÁÖÁ¦ : 2024 ´ç´¢º´ Ç÷°üÁúȯ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : À¯ÁöÀÎ
¿¬¶ôó : 02-714-9071
À̸ÞÀÏ : diabetes@kams.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í "»çÀüµî·Ï 10,000¿ø
ÇöÀåµî·Ï 20,000¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 13:00~13:15 Understanding the Pathogenesis of Atherosclerosis by Dissecting Gene Expression Profile at the Single Cell Level ÃÖÀçÈÆ(ÇѾç´ë »ý¸í°úÇаú)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 13:15~13:30 Phenotypic Plasticity of Vascular Smooth Muscle Cells in Aortic Aneurysm: Role of Mitochondria Çã°æ¼±(Ãæ³²´ë ¾àÇаú)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 13:30~13:45 Tetrahydrobiopterin is a Promising Target of Diabetic Cardiomyopathy via Restoring Mitochondria Function ±èÇü±Ô(ÀÎÁ¦ÀÇ´ë ½ÉÇ÷°ü¹× ´ë»çÁúȯ¼¾ÅÍ)
Åä·Ð 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 13:45~14:00 ÆгΠÅäÀÇ ¹× ÁúÀÇÀÀ´ä ¹Ú¿ë½Ä(°æÈñÀÇ´ë ¹Ì»ý¹°Çб³½Ç)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 14:00~14:15 Lower is Better: Optimal LDL Targets for Diabetic Patients at 55 mg/dL or 70 mg/dL? ·ùÇýÁø(°í·ÁÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 14:15~14:30 The Role of Rivaroxaban: What You Need to Know in Diabetes ÀÌ°æ¾Ö(ÀüºÏÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 14:30~14:45 SGLT2 inhibitor and GLP1-RA: Standouts as Cardioprotective Agents ¹ÚÁøÁÖ(¼¿ïÀÇ´ë ¼øȯ±â³»°ú)
Åä·Ð 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 14:45~15:00 ÆгΠÅäÀÇ ¹× ÁúÀÇÀÀ´ä ±è¹Ì°æ(°¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú)
ÈÞ½Ä 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 15:00~15:20 ÈÞ½Ä ( )
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 15:20~15:35 Vascular Factors in Diabetic Neuropathy ±èÁ¾È(ºÎõ¼¼Á¾º´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 15:35~15:50 Diabetic Nephropathy and Endothelial Dysfunction ÀüÀçÇÑ(°æºÏÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 15:50~16:05 Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Retinopathy ¾çÁö¸í(µ¿±¹ÀÇ´ë ¾È°ú)
Åä·Ð 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 16:05~16:20 ÆгΠÅäÀÇ ¹× ÁúÀÇÀÀ´ä ¿øÁ¾Ã¶(ÀÎÁ¦ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 16:20~16:35 Is It Time to Reclassify Diabetes Complications? Assessing the Adequacy of Microvascular and Macrovascular Classification ±èÁøÈ(Á¶¼±ÀÇ´ë ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 16:35~16:50 Do Type 1 and Type 2 Diabetes have the Same Vascular Complications? Á¶À±°æ(¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø ³»ºÐºñ³»°ú)
±³À°½Ã°£ 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 16:50~17:05 Diabetes Duration: Is It an Important Factor in the Occurrence of Vascular Complications? ¹èÀçÇö(°í·ÁÀÇ´ë ³»ºÐºñ³»°ú)
Åä·Ð 02¿ù 17ÀÏ aT¼¾ÅÍ 4Ãþ âÁ¶·ë 17:05~17:20 ÆгΠÅäÀÇ ¹× ÁúÀÇÀÀ´ä ¼¹ÌÇý(¼øõÇâÀÇ´ë ³»ºÐºñ³»°ú)